A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyChad J. Swanson, Jeffrey L. Cummings, Yong Zhang et al.|Alzheimer s Research & Therapy|2021Cited by 818
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s diseaseKanta Horie, Randall J. Bateman, Hong Jiang et al.|Nature Medicine|2023Cited by 249
Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cellsYutaka Machida, Nobutaka Hattori, Tomoki Chiba et al.|Biochemical and Biophysical Research Communications|2005Cited by 74
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyChad J. Swanson, Jeffrey L. Cummings, Yong Zhang et al.|Alzheimer s Research & Therapy|2022Cited by 19